Itzhak Krinsky Joins Halo Pharma Board of Directors
PTSM: Pharmaceutical Technology Sourcing and Management
Krinsky joined the board of directors at Halo after working for Teva Pharmaceuticals for 12 years.
On June 27, 2017, Halo Pharma announced the appointment of Itzhak Krinsky, PhD, to its board of directors. Krinsky has experience in the pharmaceutical industry, investment banking, and an academic career in finance and business economics. Prior to joining Halo, Krinsky worked for Teva Pharmaceuticals for 12 years. He retired from Teva earlier in 2017. During his tenure at Teva, Krinsky served as executive vice-president of Corporate Business Development, a member of the Teva executive committee, chairman of Teva Japan, chairman of Teva South Korea, and head of Business Development Asia Pacific.
Prior to joining Teva, he held various senior positions in investment banks in New York City including with Bankers Trust, Deutsche Bank, and the Silverfern Group, Inc. Krinsky also served as a professor of Finance and Business Economics at the Michael G. DeGroote School of Business, McMaster University, Ontario, Canada. He has published more than 80 articles in peer-reviewed academic journals.
Source: Halo Pharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
